EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Advanced Management of Severe Adenomyosis in IVF: A Personalized Approach With Extended GnRH Agonist and Letrozole Therapy

Charline Fatemi, Jonalyn Edades, Ibrahim ElKhatib iD, Francisco Ruiz, Laura Marqueta Marques iD, Laura Melado iD

Case Reports in Obstetrics and Gynecology · 2026-01 · 2026 (1)

DOI: 10.1155/crog/4150637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Obstetrics and Gynecology, online erschienen am 09.03.2026. Verfasst von Charline Fatemi und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, European School of Medicine, Frankfurt, Germany, medcol.mw. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study is to evaluate the effectiveness of prolonged GnRH agonist (GnRH‐a) suppression combined with letrozole and intensive luteal phase support in a patient with severe adenomyosis undergoing frozen‐thawed embryo transfer (FET).

Design

The study design was a case report.

Setting

The setting was a tertiary referral in vitro fertilization (IVF) clinic. Subjects The subject was a 41‐year‐old woman with a history of primary infertility with severe adenomyosis and endometriosis. Her partner presented with nonobstructive azoospermia. Exposure Following micro‐TESE, ovarian stimulation, and ICSI, the patient received prolonged combined GnRH‐a and letrozole suppression before two attempts of single euploid frozen embryo transfer (eFET). Main Outcome Measures The main outcome measure was pregnancy outcome.

Results

The first eFET cycle with 3 months of suppression resulted in an early miscarriage at 7 weeks. In the second cycle, a prolonged 5‐month suppression led to a significant reduction of the uterine size, lower serum estradiol levels, and optimal endometrial preparation, achieving an ongoing pregnancy and delivery of a healthy baby at 36 weeks of gestation.

Conclusion

This case supports the potential benefit of extended GnRH‐a and letrozole suppression with intensive luteal phase support for patients with severe adenomyosis, suggesting that individualized protocols may be beneficial and warrant further investigation in similar complex cases.

Schlagwörter

Stichwörter der Autor:innen

adenomyosisaromatase inhibitorseuploid blastocystfrozen embryo transferhormonal suppression

Autor:innen und Institutionen

  • College of Medicine, European School of Medicine, Frankfurt, Germany, medcol.mw.
  • Medical Department, ART Fertility Clinics Abu Dhabi, Abu Dhabi, UAE.

ORCID-Profile: Ibrahim ElKhatib, Laura Marqueta Marques, Laura Melado

Zitieren

APA

Fatemi, C., Edades, J., ElKhatib, I., Ruiz, F., Marques, L. M., & Melado, L. (2026). Advanced Management of Severe Adenomyosis in IVF: A Personalized Approach With Extended GnRH Agonist and Letrozole Therapy. Case Reports in Obstetrics and Gynecology, 2026(1). https://doi.org/10.1155/crog/4150637

Vancouver

Fatemi C, Edades J, ElKhatib I, Ruiz F, Marques LM, Melado L. Advanced Management of Severe Adenomyosis in IVF: A Personalized Approach With Extended GnRH Agonist and Letrozole Therapy. Case Reports in Obstetrics and Gynecology. 2026;2026(1). doi:10.1155/crog/4150637

BibTeX
@article{Fatemi2026,
  author = {Fatemi, Charline and Edades, Jonalyn and ElKhatib, Ibrahim and Ruiz, Francisco and Marques, Laura Marqueta and Melado, Laura},
  title = {Advanced Management of Severe Adenomyosis in IVF: A Personalized Approach With Extended GnRH Agonist and Letrozole Therapy},
  journal = {Case Reports in Obstetrics and Gynecology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crog/4150637}
}
Kostenlos starten →